A dry powder inhaler with reduced mouth-throat deposition

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 2, 2006, Pages 168-174

  Wang, Z L ^a   Grgic, B ^a   Finlay, W H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Device technology; Dry powder inhaler; Inhalation drug delivery; Mouth throat deposition; Powder deagglomeration

Indexed keywords

1,3 BUTADIENE; ACRYLONITRILE; BUDESONIDE; CIPROFLOXACIN; LACTOSE; PHOSPHOLIPID; STYRENE;

AEROSOL; ARTICLE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRY POWDER; EVALUATION; FLOW RATE; INHALATION; MOUTH; PARTICULATE MATTER; PERFORMANCE; POWDER INHALER; THROAT; ULTRAVIOLET SPECTROSCOPY;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-INFECTIVE AGENTS; BRONCHODILATOR AGENTS; BUDESONIDE; CIPROFLOXACIN; EQUIPMENT DESIGN; HUMANS; MODELS, BIOLOGICAL; MOUTH; NEBULIZERS AND VAPORIZERS; PHARYNX; POWDERS;

EID: 33745611794     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.168     Document Type: Article

References (19)

1. Finlay, W.H. 2001. The Mechanics of Inhaled Pharmaceutical Aerosols. An Introduction. Academic Press, London.
2. Hickey, A.J. 2004. Pharmaceutical Inhalation Aerosol Technology, 2nd ed. Marcel Dekker, New York.
3. Randell, T.L., K.C. Donaghue, G.R. Ambler, et al. 2003. Safety of the newer inhaled corticosteroids in childhood asthma. Paediatr. Drugs 5:481-504.
4. Finlay, W.H., and Z.L. Wang. 2003. Device and method for deagglomeration of powder. U.S. patent pending and PCT international application no. PCT/CA03/01859.
5. Stahlhofen, W., G. Rudolf, and A.C. James. 1989. Intercomparison of experimental regional aerosol deposition data. J. Aerosol Med. 2:285-308.
6. DeHaan, W.H., and W.H. Finlay. 2004. Predicting extrathoracic deposition from dry powder inhalers. J. Aerosol Sci. 35:309-331.
7. Desai, T.R., J.P. Wong, R.E.W. Hancock, et al. 2002. A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J. Pharm. Sci. 91:482-491.
8. Stapleton, K.W., E. Guentsch, M.K. Hoskinson, et al. 2000. On the suitability of k-ε turbulence modeling for aerosol deposition in the mouth and throat: a comparison with experiment. J. Aerosol Sci. 31:739-749.
9. DeHaan, W.H., and W.H. Finlay. 2001. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices. J. Aerosol Med. 14:361-367.
10. Grgic, B., W.H. Finlay, and A.F. Heenan. 2004. Regional aerosol deposition and flow measurements in an idealized mouth and throat. J. Aerosol Sci. 35:21-32.
11. Rahmatalla, M.F., P.C. Zuberbuhler, C.F. Lange, et al. 2002. In vitro effect of a holding chamber on the deposition pattern of QVAR (hydrofluoroalkane-beclomethasone dipropionate). J. Aerosol Med. 15:379-385.
12. Nichols, S.C., D.R. Brown, and M. Smurthwaite. 1998. New concept for the variable flow rate Andersen cascade impactor and calibration data. J. Aerosol Med. 11:5133-5138.
13. Borgström, L., E. Bondesson, F. Moren, et al. 1994. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with Terbutaline sulphate in normal subjects. J. Eur. Respir. 7:9-73
14. Feddah, M.R., K.F. Brown, E.M. Gipps, et al. 2000. In vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J. Pharm. Pharmaceut. Sci. 3:317-324.
15. Cameron, A., and D. Titzler. 1997. Dry Powder Inhaler Delivery system. U.S. patent no. 5622166.
16. Hoerlin, E. 1997. Capsule opening arrangement for use in a powder inhaler. WO patent no. 9727892.
17. Matida, E.A., W. DeHaan, W.H. Finlay, et al. 2003. Simulation of particle deposition in an idealized mouth with different small diameter inlets. Aerosol Sci. Tech. 37:924-932.
18. Newman, S.P., and W.W. Busse. 2002. Review: evolution of dry powder inhaler design, formulation, and performance, Respir. Med. 96:293-304.
19. Burnell, P.K.P., T. Small, S. Doig, et al. 2001. Ex vivo product performance of Diskus™ and Turbuhaler™ inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir. Med. 95:324-330.